Global Antibiotics Market – Analysis By Drug Class (Beta-Lactams, Cephalosporins, Lipopeptide, Others), Mechanism, By Region, By Country (2021 Edition): Market Insights and Forecast with Impact of COVID-19 (2021-2026)
Executive Summary
According to Azoth Analytics research report, the Global Antibiotic Market was valued at USD 46.66 Billion in the year 2020 with North America leading the regional market share. Growth in the Antibiotics Market is mainly driven by the growth of the ageing population, rising technical advancements and increasing awareness of infectious diseases in the global platform. Growing awareness, as well as investments in the development of new antibiotics in the market, is pushing the research and development as well as clinical trials in the world.
Moreover, the trend towards excessive use of antibiotics by the people is putting the risk of growing antimicrobial resistance amongst the citizens which will make the present antibiotics ineffective against disease-causing bacteria. This is forcing the world to focus more on improving the clinical research on new antibiotics in the world. With population growth and the rising geriatric population, there will be more demand for antibiotics which will push the global antibiotics market even further.
With the outbreak of the virus, as much as 95% of the people were prescribed antibiotics for their treatment. These included azithromycin, hydroxychloroquine (a chloroquine derivative of antimalarial drug) among others which proved successful for the treatment of virus during uncertain times. Many people avoided staying in the hospitals for a longer duration during the pandemic, thus prescribing antibiotics seemed the only way out. With more patients getting prescribed antibiotics, there was an increase in the demand for the same and the antibiotics market faced supply chain shortages.
Scope of the Report
According to Azoth Analytics research report, the Global Antibiotic Market was valued at USD 46.66 Billion in the year 2020 with North America leading the regional market share. Growth in the Antibiotics Market is mainly driven by the growth of the ageing population, rising technical advancements and increasing awareness of infectious diseases in the global platform. Growing awareness, as well as investments in the development of new antibiotics in the market, is pushing the research and development as well as clinical trials in the world.
Moreover, the trend towards excessive use of antibiotics by the people is putting the risk of growing antimicrobial resistance amongst the citizens which will make the present antibiotics ineffective against disease-causing bacteria. This is forcing the world to focus more on improving the clinical research on new antibiotics in the world. With population growth and the rising geriatric population, there will be more demand for antibiotics which will push the global antibiotics market even further.
With the outbreak of the virus, as much as 95% of the people were prescribed antibiotics for their treatment. These included azithromycin, hydroxychloroquine (a chloroquine derivative of antimalarial drug) among others which proved successful for the treatment of virus during uncertain times. Many people avoided staying in the hospitals for a longer duration during the pandemic, thus prescribing antibiotics seemed the only way out. With more patients getting prescribed antibiotics, there was an increase in the demand for the same and the antibiotics market faced supply chain shortages.
Scope of the Report
- The report presents the analysis of the Antibiotics market for the historical period of 2016-2020 and the forecast period of 2021-2026.
- The report analyses the Antibiotics Market by Value (USD Billion).
- The report analyses the Antibiotics Market by Drug Class (Beta-Lactams (Penicillin), Cephalosporins, Lipopeptide, Others).
- The report analyses the Antibiotics Market by Mechanism (Cell Wall Synthesis, Protein Synthesis, DNA Synthesis, Others).
- The Global Antibiotics Market has been analysed By Region (North America, Europe, Asia Pacific, LAMEA).
- The Global Antibiotics Market has been analysed By Country (United States, Canada, Germany, France, United Kingdom, Spain, Italy, China, Japan, India).
- The attractiveness of the market has been presented by region, by Drug Class and by Mechanism.
- Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.
- The report tracks competitive developments, strategies, mergers and acquisitions and product pipeline.
- The companies analysed in the report include DEINOVE, Bayer Group, Pfizer Inc., GlaxoSmithKline, Novartis AG, Eli Lilly and Company, Roche Holding AG, Amgen Inc., Johnson & Johnson and Merck KGaA.
- Antibiotics Manufacturers
- Healthcare and Pharmaceutical Companies
- Consulting and Advisory Firms
- Government and Policy Makers
- Regulatory Authorities
1. REPORT SCOPE AND METHODOLOGY
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. STRATEGIC RECOMMENDATIONS
3. ANTIBIOTICS MARKET: PRODUCT OUTLOOK
4. GLOBAL ANTIBIOTICS MARKET: SIZING AND FORECAST
4.1 Global Antibiotics Market Size, By Value, 2016-2026
5. GLOBAL ANTIBIOTICS MARKET SEGMENTATION – BY DRUG CLASS, BY MECHANISM
5.1 Competitive Scenario of Global Antibiotics Market: By Drug Class
5.1.1 Beta-Lactams (Penicillin) – Market Size and Forecast (2016-2026)
5.1.2 Cephalosporins– Market Size and Forecast (2016-2026)
5.1.3 Lipopeptides – Market Size and Forecast (2016-2026)
5.1.4 Others – Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Antibiotics Market: By Mechanism
5.2.1 Cell Wall Synthesis – Market Size and Forecast (2016-2026)
5.2.2 Protein – Market Size and Forecast (2016-2026)
5.2.3 DNA Synthesis – Market Size and Forecast (2016-2026)
5.2.4 Others – Market Size and Forecast (2016-2026)
6. GLOBAL ANTIBIOTICS MARKET: REGIONAL ANALYSIS
6.1 Competitive Scenario of Global Antibiotics Market: By Region
7. NORTH AMERICA ANTIBIOTICS MARKET: AN ANALYSIS (2016-2026)
7.1 North America Antibiotics Market: Size and Forecast (2016-2026)
7.2 North America Antibiotics Market – Prominent Companies
7.3 Market Segmentation By Drug Class (Beta-Lactams (Penicillin), Cephalosporins, Lipopeptides and Others)
7.4 Market Segmentation By Mechanism (Cell Wall Synthesis, Protein Synthesis, DNA Synthesis and Others)
7.5 North America Antibiotics Market: Country Analysis
7.6 Market Opportunity Chart of North America Antibiotics Market - By Country, By Value, 2026
7.7 Competitive Scenario of North America Antibiotics Market: By Country
7.8 United States Antibiotics Market: Size and Forecast (2016-2026), By Value
7.9 United States Antibiotics Market Segmentation - By Drug Class, By Mechanism (2016-2026)
7.10 Canada Antibiotics Market: Size and Forecast (2016-2026), By Value
7.11 Canada Antibiotics Market Segmentation - By Drug Class, By Mechanism (2016-2026)
8. EUROPE ANTIBIOTICS MARKET: AN ANALYSIS (2016-2026)
8.1 Europe Antibiotics Market: Size and Forecast (2016-2026), By Value
8.2 Europe Antibiotics Market – Prominent Companies
8.3 Market Segmentation By Drug Class (Beta-Lactams (Penicillin), Cephalosporins, Lipopeptides and Others)
8.4 Market Segmentation By Mechanism (Cell Wall Synthesis, Protein Synthesis, DNA Synthesis and Others)
8.5 Europe Antibiotics Market: Country Analysis
8.6 Market Opportunity Chart of Europe Antibiotics Market - By Country, By Value, 2026
8.7 Competitive Scenario of Europe Antibiotics Market: By Country
8.8 Germany Antibiotics Market: Size and Forecast (2016-2026), By Value
8.9 Germany Antibiotics Market Segmentation - By Drug Class, By Mechanism (2016-2026)
8.10 United Kingdom Antibiotics Market: Size and Forecast (2016-2026), By Value
8.11 United Kingdom Antibiotics Market Segmentation - By Drug Class, By Mechanism (2016-2026)
8.12 France Antibiotics Market: Size and Forecast (2016-2026), By Value
8.13 France Antibiotics Market Segmentation - By Drug Class, By Mechanism (2016-2026)
8.14 Spain Antibiotics Market: Size and Forecast (2016-2026), By Value
8.15 Spain Antibiotics Market Segmentation - By Drug Class, By Mechanism (2016-2026)
8.16 Italy Antibiotics Market: Size and Forecast (2016-2026), By Value
8.17 Italy Antibiotics Market Segmentation - By Drug Class, By Mechanism (2016-2026)
9. ASIA PACIFIC ANTIBIOTICS MARKET: AN ANALYSIS (2016-2026)
9.1 Asia Pacific Antibiotics Market: Size and Forecast (2016-2026), By Value
9.2 Asia Pacific Antibiotics Market – Prominent Companies
9.3 Market Segmentation By Drug Class (Beta-Lactams (Penicillin), Cephalosporins, Lipopeptides and Others)
9.4 Market Segmentation By Mechanism (Cell Wall Synthesis, Protein Synthesis, DNA Synthesis and Others)
9.5 Asia Pacific Antibiotics Market: Country Analysis
9.6 Market Opportunity Chart of Asia Pacific Antibiotics Market - By Country, By Value, 2026
9.7 Competitive Scenario of Asia Pacific Antibiotics Market: By Country
9.8 China Antibiotics Market: Size and Forecast (2016-2026), By Value
9.9 China Antibiotics Market Segmentation - By Drug Class, By Mechanism (2016-2026)
9.10 Japan Antibiotics Market: Size and Forecast (2016-2026), By Value
9.11 Japan Antibiotics Market Segmentation - By Drug Class, By Mechanism (2016-2026)
9.12 India Antibiotics Market: Size and Forecast (2016-2026), By Value
9.13 India Antibiotics Market Segmentation - By Drug Class, By Mechanism (2016-2026)
10. GLOBAL ANTIBIOTICS MARKET DYNAMICS
10.1 Drivers
10.2 Restraints
10.3 Trends
11. MARKET ATTRACTIVENESS
11.1 Market Attractiveness Chart of Global Antibiotics Market – By Drug Class, 2026
11.2 Market Attractiveness Chart of Global Antibiotics Market - By Mechanism, 2026
11.3 Market Attractiveness Chart of Global Antibiotics Market - By Region, 2026
12. COMPETITIVE LANDSCAPE
12.1 Major Technological Innovations, Mergers & Acquisitions and Role of Manufacturers
12.2 Product Pipeline of Leading Antibiotic Companies
12.3 Market Share Analysis
13. COMPANY ANALYSIS
13.1 DEINOVE
13.2 Bayer Group
13.3 Pfizer Inc.
13.4 GlaxoSmithKline
13.5 Novartis AG
13.6 Eli Lily and Company
13.7 Roche Holding AG
13.8 Amgen Inc.
13.9 Johnson & Johnson
13.10 Merck KGaA
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. STRATEGIC RECOMMENDATIONS
3. ANTIBIOTICS MARKET: PRODUCT OUTLOOK
4. GLOBAL ANTIBIOTICS MARKET: SIZING AND FORECAST
4.1 Global Antibiotics Market Size, By Value, 2016-2026
5. GLOBAL ANTIBIOTICS MARKET SEGMENTATION – BY DRUG CLASS, BY MECHANISM
5.1 Competitive Scenario of Global Antibiotics Market: By Drug Class
5.1.1 Beta-Lactams (Penicillin) – Market Size and Forecast (2016-2026)
5.1.2 Cephalosporins– Market Size and Forecast (2016-2026)
5.1.3 Lipopeptides – Market Size and Forecast (2016-2026)
5.1.4 Others – Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Antibiotics Market: By Mechanism
5.2.1 Cell Wall Synthesis – Market Size and Forecast (2016-2026)
5.2.2 Protein – Market Size and Forecast (2016-2026)
5.2.3 DNA Synthesis – Market Size and Forecast (2016-2026)
5.2.4 Others – Market Size and Forecast (2016-2026)
6. GLOBAL ANTIBIOTICS MARKET: REGIONAL ANALYSIS
6.1 Competitive Scenario of Global Antibiotics Market: By Region
7. NORTH AMERICA ANTIBIOTICS MARKET: AN ANALYSIS (2016-2026)
7.1 North America Antibiotics Market: Size and Forecast (2016-2026)
7.2 North America Antibiotics Market – Prominent Companies
7.3 Market Segmentation By Drug Class (Beta-Lactams (Penicillin), Cephalosporins, Lipopeptides and Others)
7.4 Market Segmentation By Mechanism (Cell Wall Synthesis, Protein Synthesis, DNA Synthesis and Others)
7.5 North America Antibiotics Market: Country Analysis
7.6 Market Opportunity Chart of North America Antibiotics Market - By Country, By Value, 2026
7.7 Competitive Scenario of North America Antibiotics Market: By Country
7.8 United States Antibiotics Market: Size and Forecast (2016-2026), By Value
7.9 United States Antibiotics Market Segmentation - By Drug Class, By Mechanism (2016-2026)
7.10 Canada Antibiotics Market: Size and Forecast (2016-2026), By Value
7.11 Canada Antibiotics Market Segmentation - By Drug Class, By Mechanism (2016-2026)
8. EUROPE ANTIBIOTICS MARKET: AN ANALYSIS (2016-2026)
8.1 Europe Antibiotics Market: Size and Forecast (2016-2026), By Value
8.2 Europe Antibiotics Market – Prominent Companies
8.3 Market Segmentation By Drug Class (Beta-Lactams (Penicillin), Cephalosporins, Lipopeptides and Others)
8.4 Market Segmentation By Mechanism (Cell Wall Synthesis, Protein Synthesis, DNA Synthesis and Others)
8.5 Europe Antibiotics Market: Country Analysis
8.6 Market Opportunity Chart of Europe Antibiotics Market - By Country, By Value, 2026
8.7 Competitive Scenario of Europe Antibiotics Market: By Country
8.8 Germany Antibiotics Market: Size and Forecast (2016-2026), By Value
8.9 Germany Antibiotics Market Segmentation - By Drug Class, By Mechanism (2016-2026)
8.10 United Kingdom Antibiotics Market: Size and Forecast (2016-2026), By Value
8.11 United Kingdom Antibiotics Market Segmentation - By Drug Class, By Mechanism (2016-2026)
8.12 France Antibiotics Market: Size and Forecast (2016-2026), By Value
8.13 France Antibiotics Market Segmentation - By Drug Class, By Mechanism (2016-2026)
8.14 Spain Antibiotics Market: Size and Forecast (2016-2026), By Value
8.15 Spain Antibiotics Market Segmentation - By Drug Class, By Mechanism (2016-2026)
8.16 Italy Antibiotics Market: Size and Forecast (2016-2026), By Value
8.17 Italy Antibiotics Market Segmentation - By Drug Class, By Mechanism (2016-2026)
9. ASIA PACIFIC ANTIBIOTICS MARKET: AN ANALYSIS (2016-2026)
9.1 Asia Pacific Antibiotics Market: Size and Forecast (2016-2026), By Value
9.2 Asia Pacific Antibiotics Market – Prominent Companies
9.3 Market Segmentation By Drug Class (Beta-Lactams (Penicillin), Cephalosporins, Lipopeptides and Others)
9.4 Market Segmentation By Mechanism (Cell Wall Synthesis, Protein Synthesis, DNA Synthesis and Others)
9.5 Asia Pacific Antibiotics Market: Country Analysis
9.6 Market Opportunity Chart of Asia Pacific Antibiotics Market - By Country, By Value, 2026
9.7 Competitive Scenario of Asia Pacific Antibiotics Market: By Country
9.8 China Antibiotics Market: Size and Forecast (2016-2026), By Value
9.9 China Antibiotics Market Segmentation - By Drug Class, By Mechanism (2016-2026)
9.10 Japan Antibiotics Market: Size and Forecast (2016-2026), By Value
9.11 Japan Antibiotics Market Segmentation - By Drug Class, By Mechanism (2016-2026)
9.12 India Antibiotics Market: Size and Forecast (2016-2026), By Value
9.13 India Antibiotics Market Segmentation - By Drug Class, By Mechanism (2016-2026)
10. GLOBAL ANTIBIOTICS MARKET DYNAMICS
10.1 Drivers
10.2 Restraints
10.3 Trends
11. MARKET ATTRACTIVENESS
11.1 Market Attractiveness Chart of Global Antibiotics Market – By Drug Class, 2026
11.2 Market Attractiveness Chart of Global Antibiotics Market - By Mechanism, 2026
11.3 Market Attractiveness Chart of Global Antibiotics Market - By Region, 2026
12. COMPETITIVE LANDSCAPE
12.1 Major Technological Innovations, Mergers & Acquisitions and Role of Manufacturers
12.2 Product Pipeline of Leading Antibiotic Companies
12.3 Market Share Analysis
13. COMPANY ANALYSIS
13.1 DEINOVE
13.2 Bayer Group
13.3 Pfizer Inc.
13.4 GlaxoSmithKline
13.5 Novartis AG
13.6 Eli Lily and Company
13.7 Roche Holding AG
13.8 Amgen Inc.
13.9 Johnson & Johnson
13.10 Merck KGaA
LIST OF FIGURES
Figure 1: Global Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 2: Number of children died from Tuberculosis, by region, 2019
Figure 3: Cause of death in children under 5 years, 2018
Figure 4: World Population 65 Years & Above (% of Total), 2015-2019
Figure 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 6: Global Consumption of antibiotics in WHO countries, 2016 (In metric tonnes)
Figure 7: Global Antibiotics Market- By Drug Class Market Share, 2020 & 2026
Figure 8: Global Antibiotics Market- By Beta-Lactams (Penicillin) , By Value (USD Million), 2016-2026
Figure 9: Global Antibiotics Market- By Cephalosporins, By Value (USD Million), 2016-2026
Figure 10: Global Antibiotics Market- By Lipopeptides, By Value (USD Million), 2016-2026
Figure 11: Global Antibiotics Market- By Others, By Value (USD Million), 2016-2026
Figure 12: Global Antibiotics Market- By Mechanism Market Share, 2020 & 2026
Figure 13: Global Antibiotics Market- By Cell Wall Synthesis, By Value (USD Million), 2016-2026
Figure 14: Global Antibiotics Market- By Protein Synthesis, By Value (USD Million), 2016-2026
Figure 15: Global Antibiotics Market- By DNA Synthesis, By Value (USD Million), 2016-2026
Figure 16: Global Antibiotics Market- By Others, By Value (USD Million), 2016-2026
Figure 17: Global Antibiotics Market- By Region Market Share, 2020 & 2026
Figure 18: North America Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 19: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 20: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 21: North America Urban population, 2015-2018 (In %)
Figure 22: North America Antibiotic players market share (%), 2020
Figure 23: North America Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 24: North America Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 25: Market Opportunity Chart of North America Antibiotics Market- By Country, By Value (Year 2016-2026)
Figure 26: North America Antibiotics Market- By Country Market Share, 2020 & 2026
Figure 27: United States Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 28: United States year-on-year growth of antibiotics (in %), (2017-2026)
Figure 29: United States population aged 65 and above, (in % of total population), 2016-2020
Figure 30: United States health expenditure (% of GDP), 2013-2018
Figure 31: United States Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 32: United States Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 33: Canada Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 34: Canada population aged 65 and above (% of total population), 2016-2020
Figure 35: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 36: Canada Urban population, 2015-2019 (In %)
Figure 37: Canada Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 38: Canada Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 39: Europe Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 40: Europe current health expenditure (% of GDP), (2014-2018)
Figure 41: Europe total consumption of antibiotics among countries (in metric tonnes), (2016)
Figure 42: Europe median number of deaths due to antibiotic resistance bacteria, (2015)
Figure 43: Europe Antibiotic players market share (%), 2020
Figure 44: Europe Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 45: Europe Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 46: Market Opportunity Chart of Europe Antibiotics Market- By Country, By Value (Year 2016-2026)
Figure 47: Europe Antibiotics Market- By Country Market Share, 2020 & 2026
Figure 48: Germany Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 49: Germany current health expenditure (% of GDP), (2014-2018)
Figure 50: Germany population aged 65 and above (% of total population), 2016-2020
Figure 51: Germany antimicrobial resistant indicators (% of isolated tested), 2020
Figure 52: Germany Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 53: Germany Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 54: United Kingdom Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 55: United Kingdom current health expenditure (% of GDP), (2014-2018)
Figure 56: United Kingdom population aged 65 and above (% of total population), 2016-2020
Figure 57: United Kingdom urban population (in millions), 2016-2020
Figure 58: United Kingdom Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 59: United Kingdom Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 60: France Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 61: France current health expenditure (% of GDP), (2014-2018)
Figure 62: France consumption of antibiotics (defined daily doses per 1000 inhabitants per day), 2012-2016
Figure 63: France population aged 65 and above (% of total population), 2016-2020
Figure 64: France Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 65: France Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 66: Spain Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 67: Spain current health expenditure (% of GDP), (2014-2018)
Figure 68: Spain population aged 65 and above (% of the total population), 2016-2020
Figure 69: Spain share of individuals consuming antibiotics, 2018
Figure 70: Spain Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 71: Spain Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 72: Italy Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 73: Italy current health expenditure (% of GDP), (2014-2018)
Figure 74: Italy population aged 65 and above (% of total population), 2016-2020
Figure 75: Italy antimicrobial resistant indicators (% of isolated tests), 2020
Figure 76: Italy Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 77: Italy Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 78: Asia Pacific Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 79: Asia Pacific antimicrobial use (daily defined doses in millions), 2020
Figure 80: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 81: Asia Pacific Incidence of tuberculosis per 100,000 people, 2019
Figure 82: Asia Pacific Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 83: Asia Pacific Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 84: Market Opportunity Chart of APAC Antibiotics Market- By Country, By Value (Year-2026)
Figure 85: APAC Antibiotics Market- By Country Market Share, 2020 & 2026
Figure 86: China Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 87: China total population in billions), 2016-2020
Figure 88: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 89: China export of antibiotics to US, 2019, in USD Million
Figure 90: China Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 91: China Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 92: Japan Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 93: Japan population above 65 years (% of total population), 2016-2020
Figure 94: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
Figure 95: Japan urban population (in millions), 2016-2020
Figure 96: Japan Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 97: Japan Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 98: India Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 99: India Current Healthcare Expenditure (% of GDP), 2015-2018
Figure 100: India population (in billions), 2016-2020
Figure 101: India antimicrobial resistant indicators(% of isolated tested), 2020
Figure 102: India Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 103: India Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 104: Market Attractiveness Chart of Global Antibiotics Market- By Drug Class (Year-2016-2026)
Figure 105: Market Attractiveness Chart of Global Antibiotics Market- By Mechanism (Year 2016-2026)
Figure 106: Market Attractiveness Chart of Global Antibiotics Market- By Region (Year 2016-2026)
Figure 107: Global Antibiotic players market share (%), 2020
Figure 108: DEINOVE Sales Revenues, 2016-2020 (USD Million)
Figure 109: DEINOVE Loss, 2016-2020 (USD Million)
Figure 110: Bayer Group Sales Revenues, 2016-2020 (USD Million)
Figure 111: Bayer Group Net Profit, 2016-2020 (USD Million)
Figure 112: Bayer Group, By Business Segment (%), FY2020
Figure 113: Bayer Group, By Geographical Segment (%), FY2020
Figure 114: Pfizer Inc., Annual Sales Revenue (USD Million), 2016-2020
Figure 115: Pfizer Inc., Annual Net Income/Loss (USD Million), 2016-2020
Figure 116: Pfizer Inc., sales Revenue, By Geographical Segment (%), FY2020
Figure 117: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020
Figure 118: GlaxoSmithKline Gross Profit (USD Million), 2016-2020
Figure 119: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020
Figure 120: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020
Figure 121: Novartis Annual Sales Revenue (USD Million), 2016-2020
Figure 122: Novartis Annual Net Income/Loss (USD Million), 2016-2020
Figure 123: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 124: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
Figure 125: Eli Lilly and Company Annual Sales Revenue (USD Million), 2016-2020
Figure 126: Eli Lilly and Company Annual Net Income (USD Million), 2016-2020
Figure 127: Eli Lilly and Company Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 128: Eli Lilly and Company Sales Revenue Split, By Geography Segment (%), FY2020
Figure 129: Roche Holding AG Sales Revenues, 2016-2020 (USD Million)
Figure 130: Roche Holding AG Net Income, 2016-2020 (USD Million)
Figure 131: Roche Holding AG sales Revenues, By Business Segment (%), FY2020
Figure 132: Roche Holding AG sales Revenue, By Geographical Segment (%), FY2020
Figure 133: Amgen Inc. Sales Revenues, 2016-2020 (USD Million)
Figure 134: Amgen Inc. Net Income, 2016-2020 (USD Million)
Figure 135: Amgen Inc. Sales Revenue Split, By Business Segment (%), FY2020
Figure 136: Amgen Inc. Sales Revenue Split, By Geography Segment (%), FY2020
Figure 137: Johnson & Johnson Annual Sales Revenue (USD Billion), 2016-2020
Figure 138: Johnson & Johnson Annual Net Income/Loss (USD Billion), 2016-2020
Figure 139: Johnson & Johnson Sales Revenue Split, By Business Segment (%), FY2020
Figure 140: Johnson & Johnson Sales Revenue Split, By Geography Segment (%), FY2020
Figure 141: Merck KGaA Sales Revenues, 2016-2020 (USD Million)
Figure 142: Merck KGaA Gross Profit, 2016-2020 (USD Million)
Figure 143: Merck KGaA Sales Revenue Split, By Business Segment (%), FY2020
Figure 144: Merck KGaA Sales Revenue Split, By Geography Segment (%), FY2020
Figure 1: Global Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 2: Number of children died from Tuberculosis, by region, 2019
Figure 3: Cause of death in children under 5 years, 2018
Figure 4: World Population 65 Years & Above (% of Total), 2015-2019
Figure 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 6: Global Consumption of antibiotics in WHO countries, 2016 (In metric tonnes)
Figure 7: Global Antibiotics Market- By Drug Class Market Share, 2020 & 2026
Figure 8: Global Antibiotics Market- By Beta-Lactams (Penicillin) , By Value (USD Million), 2016-2026
Figure 9: Global Antibiotics Market- By Cephalosporins, By Value (USD Million), 2016-2026
Figure 10: Global Antibiotics Market- By Lipopeptides, By Value (USD Million), 2016-2026
Figure 11: Global Antibiotics Market- By Others, By Value (USD Million), 2016-2026
Figure 12: Global Antibiotics Market- By Mechanism Market Share, 2020 & 2026
Figure 13: Global Antibiotics Market- By Cell Wall Synthesis, By Value (USD Million), 2016-2026
Figure 14: Global Antibiotics Market- By Protein Synthesis, By Value (USD Million), 2016-2026
Figure 15: Global Antibiotics Market- By DNA Synthesis, By Value (USD Million), 2016-2026
Figure 16: Global Antibiotics Market- By Others, By Value (USD Million), 2016-2026
Figure 17: Global Antibiotics Market- By Region Market Share, 2020 & 2026
Figure 18: North America Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 19: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 20: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 21: North America Urban population, 2015-2018 (In %)
Figure 22: North America Antibiotic players market share (%), 2020
Figure 23: North America Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 24: North America Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 25: Market Opportunity Chart of North America Antibiotics Market- By Country, By Value (Year 2016-2026)
Figure 26: North America Antibiotics Market- By Country Market Share, 2020 & 2026
Figure 27: United States Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 28: United States year-on-year growth of antibiotics (in %), (2017-2026)
Figure 29: United States population aged 65 and above, (in % of total population), 2016-2020
Figure 30: United States health expenditure (% of GDP), 2013-2018
Figure 31: United States Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 32: United States Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 33: Canada Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 34: Canada population aged 65 and above (% of total population), 2016-2020
Figure 35: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 36: Canada Urban population, 2015-2019 (In %)
Figure 37: Canada Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 38: Canada Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 39: Europe Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 40: Europe current health expenditure (% of GDP), (2014-2018)
Figure 41: Europe total consumption of antibiotics among countries (in metric tonnes), (2016)
Figure 42: Europe median number of deaths due to antibiotic resistance bacteria, (2015)
Figure 43: Europe Antibiotic players market share (%), 2020
Figure 44: Europe Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 45: Europe Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 46: Market Opportunity Chart of Europe Antibiotics Market- By Country, By Value (Year 2016-2026)
Figure 47: Europe Antibiotics Market- By Country Market Share, 2020 & 2026
Figure 48: Germany Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 49: Germany current health expenditure (% of GDP), (2014-2018)
Figure 50: Germany population aged 65 and above (% of total population), 2016-2020
Figure 51: Germany antimicrobial resistant indicators (% of isolated tested), 2020
Figure 52: Germany Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 53: Germany Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 54: United Kingdom Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 55: United Kingdom current health expenditure (% of GDP), (2014-2018)
Figure 56: United Kingdom population aged 65 and above (% of total population), 2016-2020
Figure 57: United Kingdom urban population (in millions), 2016-2020
Figure 58: United Kingdom Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 59: United Kingdom Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 60: France Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 61: France current health expenditure (% of GDP), (2014-2018)
Figure 62: France consumption of antibiotics (defined daily doses per 1000 inhabitants per day), 2012-2016
Figure 63: France population aged 65 and above (% of total population), 2016-2020
Figure 64: France Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 65: France Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 66: Spain Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 67: Spain current health expenditure (% of GDP), (2014-2018)
Figure 68: Spain population aged 65 and above (% of the total population), 2016-2020
Figure 69: Spain share of individuals consuming antibiotics, 2018
Figure 70: Spain Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 71: Spain Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 72: Italy Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 73: Italy current health expenditure (% of GDP), (2014-2018)
Figure 74: Italy population aged 65 and above (% of total population), 2016-2020
Figure 75: Italy antimicrobial resistant indicators (% of isolated tests), 2020
Figure 76: Italy Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 77: Italy Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 78: Asia Pacific Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 79: Asia Pacific antimicrobial use (daily defined doses in millions), 2020
Figure 80: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 81: Asia Pacific Incidence of tuberculosis per 100,000 people, 2019
Figure 82: Asia Pacific Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 83: Asia Pacific Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 84: Market Opportunity Chart of APAC Antibiotics Market- By Country, By Value (Year-2026)
Figure 85: APAC Antibiotics Market- By Country Market Share, 2020 & 2026
Figure 86: China Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 87: China total population in billions), 2016-2020
Figure 88: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 89: China export of antibiotics to US, 2019, in USD Million
Figure 90: China Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 91: China Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 92: Japan Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 93: Japan population above 65 years (% of total population), 2016-2020
Figure 94: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
Figure 95: Japan urban population (in millions), 2016-2020
Figure 96: Japan Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 97: Japan Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 98: India Antibiotics Market Size, By Value, 2016-2026 (USD Million)
Figure 99: India Current Healthcare Expenditure (% of GDP), 2015-2018
Figure 100: India population (in billions), 2016-2020
Figure 101: India antimicrobial resistant indicators(% of isolated tested), 2020
Figure 102: India Antibiotics Market- By Drug Class, By Value (USD Million), 2016-2026
Figure 103: India Antibiotics Market- By Mechanism, By Value (USD Million), 2016-2026
Figure 104: Market Attractiveness Chart of Global Antibiotics Market- By Drug Class (Year-2016-2026)
Figure 105: Market Attractiveness Chart of Global Antibiotics Market- By Mechanism (Year 2016-2026)
Figure 106: Market Attractiveness Chart of Global Antibiotics Market- By Region (Year 2016-2026)
Figure 107: Global Antibiotic players market share (%), 2020
Figure 108: DEINOVE Sales Revenues, 2016-2020 (USD Million)
Figure 109: DEINOVE Loss, 2016-2020 (USD Million)
Figure 110: Bayer Group Sales Revenues, 2016-2020 (USD Million)
Figure 111: Bayer Group Net Profit, 2016-2020 (USD Million)
Figure 112: Bayer Group, By Business Segment (%), FY2020
Figure 113: Bayer Group, By Geographical Segment (%), FY2020
Figure 114: Pfizer Inc., Annual Sales Revenue (USD Million), 2016-2020
Figure 115: Pfizer Inc., Annual Net Income/Loss (USD Million), 2016-2020
Figure 116: Pfizer Inc., sales Revenue, By Geographical Segment (%), FY2020
Figure 117: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020
Figure 118: GlaxoSmithKline Gross Profit (USD Million), 2016-2020
Figure 119: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020
Figure 120: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020
Figure 121: Novartis Annual Sales Revenue (USD Million), 2016-2020
Figure 122: Novartis Annual Net Income/Loss (USD Million), 2016-2020
Figure 123: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 124: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
Figure 125: Eli Lilly and Company Annual Sales Revenue (USD Million), 2016-2020
Figure 126: Eli Lilly and Company Annual Net Income (USD Million), 2016-2020
Figure 127: Eli Lilly and Company Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 128: Eli Lilly and Company Sales Revenue Split, By Geography Segment (%), FY2020
Figure 129: Roche Holding AG Sales Revenues, 2016-2020 (USD Million)
Figure 130: Roche Holding AG Net Income, 2016-2020 (USD Million)
Figure 131: Roche Holding AG sales Revenues, By Business Segment (%), FY2020
Figure 132: Roche Holding AG sales Revenue, By Geographical Segment (%), FY2020
Figure 133: Amgen Inc. Sales Revenues, 2016-2020 (USD Million)
Figure 134: Amgen Inc. Net Income, 2016-2020 (USD Million)
Figure 135: Amgen Inc. Sales Revenue Split, By Business Segment (%), FY2020
Figure 136: Amgen Inc. Sales Revenue Split, By Geography Segment (%), FY2020
Figure 137: Johnson & Johnson Annual Sales Revenue (USD Billion), 2016-2020
Figure 138: Johnson & Johnson Annual Net Income/Loss (USD Billion), 2016-2020
Figure 139: Johnson & Johnson Sales Revenue Split, By Business Segment (%), FY2020
Figure 140: Johnson & Johnson Sales Revenue Split, By Geography Segment (%), FY2020
Figure 141: Merck KGaA Sales Revenues, 2016-2020 (USD Million)
Figure 142: Merck KGaA Gross Profit, 2016-2020 (USD Million)
Figure 143: Merck KGaA Sales Revenue Split, By Business Segment (%), FY2020
Figure 144: Merck KGaA Sales Revenue Split, By Geography Segment (%), FY2020
LIST OF TABLES:
Table A: Product Pipeline of Leading Antibiotic Companies – DEINOVE
Table B: Clinical Pipeline of Antibiotics Development
Table C: Product Pipeline of Leading Antibiotics Companies
Table A: Product Pipeline of Leading Antibiotic Companies – DEINOVE
Table B: Clinical Pipeline of Antibiotics Development
Table C: Product Pipeline of Leading Antibiotics Companies
